Cardiovascular risk: Prevention and treatment of the metabolic syndrome. Export

@article{citeulike:229176, abstract = {The metabolic syndrome is a cluster of metabolic abnormalities, including impaired glucose metabolism, hypertension, dyslipidemia and abdominal obesity. It is a precursor to type 2 diabetes and a powerful independent risk factor for cardiovascular disease. Lifestyle changes, such as a diet high in saturated fats and a lack of physical exercise, have contributed to a worldwide increase in the prevalence of the metabolic syndrome and its associated complications. Identification and effective management of patients with the metabolic syndrome is important to reduce their risk of subsequent disease. Lifestyle modifications are an essential first step, and lipid-lowering therapy may also be required to achieve the lipid goals set out in current treatment guidelines. Statins are the most effective class of lipid-lowering drugs. Recent studies in patients with type 2 diabetes or the metabolic syndrome have shown that rosuvastatin was more effective than atorvastatin, simvastatin or pravastatin in reducing low-density lipoprotein cholesterol and enabling patients to reach lipid goals.}, address = {University of Helsinki and National Public Health Institute, Mannerheimintie 166, Helsinki FIN-00300, Finland.}, author = {Tuomilehto, J.}, citeulike-article-id = {229176}, citeulike-linkout-0 = {http://dx.doi.org/10.1016/j.diabres.2005.03.018}, citeulike-linkout-1 = {http://view.ncbi.nlm.nih.gov/pubmed/15953504}, citeulike-linkout-2 = {http://www.hubmed.org/display.cgi?uids=15953504}, doi = {10.1016/j.diabres.2005.03.018}, issn = {0168-8227}, journal = {Diabetes Res Clin Pract}, keywords = {cardiovascular, diabetes, risk}, month = {June}, posted-at = {2005-06-28 11:39:23}, priority = {2}, title = {Cardiovascular risk: Prevention and treatment of the metabolic syndrome.}, url = {http://dx.doi.org/10.1016/j.diabres.2005.03.018}, volume = {68 Suppl 2}, year = {2005} }

TY - JOUR ID - citeulike:229176 L3 - citeulike-article-id:229176 N2 - The metabolic syndrome is a cluster of metabolic abnormalities, including impaired glucose metabolism, hypertension, dyslipidemia and abdominal obesity. It is a precursor to type 2 diabetes and a powerful independent risk factor for cardiovascular disease. Lifestyle changes, such as a diet high in saturated fats and a lack of physical exercise, have contributed to a worldwide increase in the prevalence of the metabolic syndrome and its associated complications. Identification and effective management of patients with the metabolic syndrome is important to reduce their risk of subsequent disease. Lifestyle modifications are an essential first step, and lipid-lowering therapy may also be required to achieve the lipid goals set out in current treatment guidelines. Statins are the most effective class of lipid-lowering drugs. Recent studies in patients with type 2 diabetes or the metabolic syndrome have shown that rosuvastatin was more effective than atorvastatin, simvastatin or pravastatin in reducing low-density lipoprotein cholesterol and enabling patients to reach lipid goals. JF - Diabetes Res Clin Pract SN - 0168-8227 AD - University of Helsinki and National Public Health Institute, Mannerheimintie 166, Helsinki FIN-00300, Finland. TI - Cardiovascular risk: Prevention and treatment of the metabolic syndrome. VL - 68 Suppl 2 KW - cardiovascular KW - diabetes KW - risk AU - Tuomilehto, J PY - 2005/06// UR - http://dx.doi.org/10.1016/j.diabres.2005.03.018 ER -